HIV infected cell

ViiV in late-stage HIV trial success

pharmafile | September 23, 2015 | News story | Research and Development HIV, Triumeq, ViiV, virology 

Switching patients to Triumeq, a once-daily combination treatment for HIV, is as effective as remaining on antiretroviral therapy in certain patients with HIV infection.

The STRIIVING study looked at the benefits of switching patients from Triumeq (abacavir/dolutegravir/lamivudine) from antiretroviral therapy (ART). It included 277 virologically suppressed adults who remained on their existing ART for six months. 

STRIIVING met its primary endpoint, demonstrating that viral suppression – defined as the time to the first of at least two consecutive undetectable measurements of HIV viral load. In both the group of patients who switched to Triumeq from ART, and the group which remained on ART, 93% showed viral suppression at the end of the study period.

Furthermore the treatment satisfaction score improvement was statistically significantly for more patients switching to Triumeq from their established regimen, as assessed by the HIV Treatment Satisfaction Questionnaire.

Dr John Pottage, who is chief scientific and medical officer at ViiV Healthcare, which manaufactures Triumeq, says: “For clinicians, choosing among antiretroviral therapies now involves balancing efficacy with factors such as tolerability, dosing, ability to use with other medications, and resistance profile. These data support the use of once-daily abacavir/dolutegravir/lamivudine as a treatment option in the switch setting for appropriate patients.”

Lilian Anekwe

Related Content

Gilead and Merck share data from phase 2 trial of HIV treatment

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …

Latest content